Olema (OLMA) CFO Jason O'Byrne Receives 650,000-Share Award

What Happened

• Jason O'Byrne, Chief Financial Officer of Olema Pharmaceuticals (OLMA), received a derivative award for 650,000 shares reported on Sep 1, 2026. The filing lists an acquisition at $0.00 per share (no cash paid reported). This is an award/grant (not a sale or exercise).

Key Details

• Transaction date: 2026-09-01; Report filed: 2026-09-02 (appears timely).
• Transaction type/code: A (Grant/award — derivative); Reported price: $0.00; Shares granted: 650,000.
• Shares owned after transaction: not disclosed in the provided filing.
• Footnote: 25% of the shares subject to the option vest on August 11, 2027, then 1/48 of the total shares vest each month thereafter, subject to continuous service through each vesting date.

Context

• The award is a derivative grant with a multi‑year vesting schedule, so the shares are not immediately transferable or realizable until they vest. This is a common form of executive compensation intended to retain and incentivize management; it is not an immediate sale or exercise.